Latest common stock for VRDN: $1.1M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
Viridian Therapeutics (VRDN) currently reports a common stock of $1.1M as of June 2026. That compares with $820K in the prior-year period — up 38.6% year over year. Use the charts on this page to explore Viridian Therapeutics's common stock history and peer comparisons.
Viridian Therapeutics's common stock increased from $820K to $1.1M — a 38.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Viridian Therapeutics reported $1.1M in common stock as of June 2026. That compares with $820K in the prior-year period — up 38.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current common stock of $1.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Viridian Therapeutics, and consider following VRDN for alerts when major investors trade the stock.
Viridian Therapeutics is classified in the Healthcare sector. On common stock, it currently shows $1.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VRDN with unrelated industries.